Several factors influence tirzepatide's pharmacokinetics: Elimination pathway : Tirzepatide is primarily eliminated through proteolytic breakdown in the body, not through renal excretion Dose and duration of treatment : Higher doses and longer treatment periods result in greater drug accumulation Body weight : Body weight is a known covariate that can modestly affect drug exposure Steady-state concentrations : With weekly dosing, tirzepatide reaches steady-state levels after approximately 4 weeks of consistent administration According to FDA prescribing information, no dose adjustment is required for patients with renal impairment (including end-stage renal disease) or hepatic impairment, as these conditions do not significantly affect tirzepatide clearance
HealthPost is a Certified B Corporation and Zero Carbon certified with Ekos, and supports conservation through the HealthPost Nature Trust
Easy measuring: At 6.67 mg/mL total, 1 unit = 0.01 mL 66.7 mcg total (~33.3 mcg of each peptide) on a U-100 insulin syringe
Advances in Therapy , 37(3), 1087-1099
Talk to your veterinarian about any side effect that seems unusual or bothersome to your pet
Research hypotheses include: Lipolysis and Fatty-Acid Oxidation: Possible activation of adipocyte lipase or modulation of acetyl-CoA carboxylase activity
